


The Cambridge Structural Database: a Powerful Resource in Drug Discovery




Juliette Pradon and Ilaria Giangreco

The Cambridge Crystallographic Data Centre, Cambridge, UK. E-mail: pradon@ccdc.cam.ac.uk; Web: <http://www.ccdc.cam.ac.uk>

THE CAMBRIDGE STRUCTURAL DATABASE (CSD)




Successful modern drug discovery research makes extensive use of structural data – from target proteins, candidate drug molecules, and complexes of the two. The value of protein-ligand structural information is well accepted, however, knowledge of molecular conformations and interactions derived from small molecule structures alone can have a significant impact in drug discovery. This year commemorates a milestone for structural chemistry as the CSD has reached the addition of its **millionth** structure to its extensive repository of fully curated organic and metal-organic structures.




Inside the CSD

The CSD doesn't just contain purely crystallographic data; it also provides a wealth of information on things like melting points, crystal morphology, etc. As well as Crystallographic Information Frameworks (CIFs) destined for the CSD we also make available a number of other CIFs that don't fit the criteria

for the CSD through our Access Structures service: <https://www.ccdc.cam.ac.uk/structures/>. These datasets include calculated structures and can be linked to from a publication.




CSD-CROSSMINER




- Which structural motifs bind similar protein binding sites?
- Which ligand motifs have similar protein interaction patterns?
- Which ligand modifications and scaffold hops are tolerated in a protein binding site?

CSD-CrossMiner¹ provides the ability to search structural databases in terms of pharmacophore queries allowing to design molecular mimics of established lead compounds, shed some light on the cross-pharmacology between protein targets, as well as on the selectivity of bioactive small molecules.


Kinase Inhibitor Scaffold Hopping Based on Ligand Features




Aim: replace the pyrimidine ring to find new potent tyrosine kinase inhibitors.




Results: we found hits from the CSD with a different central ring, e.g. IDUQOO with a pyrrole ring. In addition, we found solutions where the central ring is replaced by an urea moiety able to form an intramolecular H-bond.




Finding Isosteres for Spleen Tyrosine Kinase (Syk) Inhibitors



Aim: find isosteres of the 1,6-naphthyridine ring to obtain more potent and selective analogs while preserving the molecular interaction pattern.



Results: we found hits from the CSD with an isothiazole as an isostere of the 1,6-naphthyridine ring.




By searching the PDB we found that there is a risk of cross-reactivity between Syk protein and Aurora kinase (EC 2.7.11.1). This cross-reactivity is also detected in vivo³.


Results List					
mark identifier	cluster	rimd	chain	deposition_date	ec_number
3EFV_m1_A-pi_090_A_1,1	385	0.695	A	2008-08-19	2.7.11.1
3F7A_m1_A-pi_090_A_1,1	381	0.695	B	2008-08-19	2.7.10.2
4P9N_m1_A-pi_091_A_1,1	383	0.695	A	2013-07-10	2.7.11.1
4PNN_m1_A-pi_092_A_1,1	383	0.695	A	2014-09-24	24.23.0
4UQX_m1_A-pi_011_A_1,1	382	0.695	A	2013-09-27	2.7.10.1
4XQX_m1_A-pi_012_A_1,1	383	0.695	A	2013-09-16	2.7.10.0
2KEX_m1_A-pi_013_A_1,1	387	0.696	A	2013-09-14	2.5.1.78
4KQ6_m1_A-pi_014_A_1,1	386	0.696	J	1995-09-18	3.1.1.7
2D7D_m1_A-pi_015_A_1,1	382	0.697	A	2009-09-29	2.7.11.1
3KGF_m1_A-pi_016_A_1,1	390	0.697	A	2009-03-05	2.7.11.24
3PMN_m1_A-pi_017_A_1,1	394	0.697	A	2010-11-17	2.7.7
4CCR_m1_B-pi_018_A_1,1	394	0.697	D	2013-10-25	1.8.1.9
4IBP_m1_B-pi_019_A_1,1	391	0.697	A	2013-08-20	2.7.11.1
5K9W_m1_A-pi_019_A_1,1	388	0.697	A	2016-09-03	2.7.11.1

FROM DATA TO KNOWLEDGE



Here are two examples showing the value that can be obtained from the fully curated database and consider the intelligent software required to extract powerful insights that can inform the design, development and identification of new and better pharmaceutical products.



Molecular Shape



Molecular Interactions



Applications

- Validation of molecular geometries.
- Conformational generation and validation for identification of low energy conformations^{5,6}.
- Creation of restraint data/ligand dictionaries for protein crystallographers and structural biologists.

Applications

- Analyse the interaction preferences of molecules⁸.
- Obtain evaluation of intermolecular packing of a crystal structure, e.g. evaluate the stability of polymorphic structures.
- Obtain interaction preferences for cavities in proteins⁹.

1: Korb et al., (2016), *J. Med. Chem.*, **59**, 4257-4266.

2: Furet et al., (2008), *Bioorg. Med. Chem. Lett.*, **18**, 897-900.

3: Thoma et al., (2015), *Bioorg. Med. Chem. Lett.*, **25**, 4642-4647.

4: Bruno et al., (2004), *J. Chem. Comput. Sci.*, **44**, 2133-2144.

5: Nils-Ole et al., (2017), *J. Chem. Inf. Model.*, **57**, 2719-2728.

6: Cole et al., (2018), *J. Chem. Inf. Model.*, **58**, 615-629.

7: Bruno et al., (1997), *J. Comput.-Aided Mol. Des.*, **11**, 525-537.

8: Wood et al., (2013), *CrystEngComm*, **15**, 65-72.

9: Verdonk et al., (1999), *J. Mol. Biol.*, **289**, 1093-1108.